Autolus Therapeutics (NASDAQ:AUTL) is seeking to differentiate itself in the CAR-T market by pairing strong clinical activity ...

Management will host a conference call and webcast at 8:30am EDT / 12:30pm GMT to discuss the company’s financial results and provide a general business update. Conference call participants should pre ...

Detailed price information for Autolus Therapeutics Plc ADR (AUTL-Q) from The Globe and Mail including charting and trades.

Detailed price information for Autolus Therapeutics Plc ADR (AUTL-Q) from The Globe and Mail including charting and trades.

Autolus Therapeutics (NASDAQ:AUTL) hosted an investor event focused on its acute lymphoblastic leukemia (ALL) program, ...

Cell therapy developer Autolus has a lead program under FDA review for a type of blood cancer and in clinical development for other indications. As the company looks ahead to a potential product ...

Autolus Therapeutics plc has a PDUFA date upcoming for its cell therapy obe-cel, indicated for B-ALL. The FDA will decide whether to approve the drug for commercial use. There is already a cell ...

Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2025 Earnings Call Transcript March 27, 2026 Autolus Therapeutics plc misses on ...

Autolus Therapeutics (NASDAQ:AUTL) is gearing up to announce its quarterly earnings on Wednesday, 2025-11-12. Here's a quick overview of what investors should know before the release. Analysts are ...

Autolus plans to sell 75 million American depositary shares at a price of $2 each. The proceeds will be used to fund the development of the company's obe-cell cancer cell therapy. Autolus said that it ...

Autolus Therapeutics signed an option and license agreement with Moderna for up to four immuno-oncology targets. Autolus is developing a whole new class of reprogrammed T-cell therapies to treat ...